CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial

Open access
Yin, Ting-Ting, Bi, Yan, Li, Ping, Shen, Shan-Mei, Wang, Wei-Min, Jiang, Can, Gao, Cai-Xia, Wang, Yan, Gao, Li-Jun, Zhu, Da-Long, Feng, Wen-Huan · 2018 · Nutrition & Metabolism

Abstract

BACKGROUND: Weight loss, especially fat mass reduction, helps to improve blood glucose control, insulin sensitivity, and β-cell function. This study aimed to compare the effect of exenatide and glargine on body composition in overweight and obese patients with type 2 diabetes (T2DM) who do not achieve adequate glycemic control with metformin. METHODS: We performed a prospective, randomized study of 37 overweight or obese patients with T2DM who had inadequate glycemic control with metformin. The patients were treated with either exenatide or glargine for 16 weeks. Dual-energy X-ray absorptiometry was used to assess body composition. RESULTS: Post-intervention weight, body mass index (BMI), waist circumference, body mass, and fat mass were lower in patients treated with exenatide, while weight and BMI significantly increased with glargine. Reductions in weight, BMI, body fat mass, and percent fat mass (except for gynoid) were greater with exenatide than with glargine, and percent lean tissue (other than the limbs) increased with exenatide. In all body regions except for the limbs, fat mass decreased with exenatide to a greater extent than lean tissue. Glucose control, insulin resistance, and β-cell function were not different between the treatment groups. CONCLUSIONS: For overweight and obese patients whose T2DM was inadequately controlled with metformin, exenatide and glargine achieved similar improvements in glycemic control, insulin sensitivity, and β-cell function.However, exenatide produced better weight and fat mass reduction, which were beneficial for blood glucose control. Our findings may guide the selection of appropriate drugs for glycemic and weight control. TRIAL REGISTRATION: NCT02325960, registered 25 December 2014.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12986-018-0295-6

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flow chart of the study participants
Fig. 1 Flow chart of the study participantsCC BY · PubMed Central
Fig. 2 Changes in fat mass and lean tissue in the total body, trunk, limbs, and android and gynoid regions following exenatide treatment
Fig. 2 Changes in fat mass and lean tissue in the total body, trunk, limbs, and android and gynoid regions following exenatide treatmentCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 26

Metadata

Authors
Yin, T.-T., Bi, Y., Li, P., Shen, S.-M., Wang, W.-M., Jiang, C., Gao, C.-X., Wang, Y., Gao, L.-J., Zhu, D.-L., & Feng, W.-H.
Affiliations
  • Nanjing Drum Tower Hospital (CN)
  • Jining First People's Hospital (CN)
Venue
Nutrition & Metabolism
Published
2018-10-01
Volume
15
Issue
1
Pages
67-67
ISSN
1743-7075 (ISSN-L)
OpenAlex
W2893958327
Cited by
26
References
46
Citations by year
2026: 8 · 2025: 5 · 2024: 2 · 2021: 4 · 2020: 1 · 2019: 5
FWCI
1.99
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Nutrition & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
Funders
  • AstraZeneca
  • National Natural Science Foundation of China (81570737, 2017-N-05, 81570736, 2015604, 14380296)
  • Government of Jiangsu Province
  • Nanjing University (14380296)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
exenatide, insulin glargine, type 2 diabetes, obesity, overweight, body composition, fat mass reduction, lean tissue, glycemic control, insulin resistance, beta-cell function, weight loss

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s12986-018-0295-6
The paper
Yin, T.-T., Bi, Y., Li, P., Shen, S.-M., Wang, W.-M., Jiang, C., Gao, C.-X., Wang, Y., Gao, L.-J., Zhu, D.-L., & Feng, W.-H. (2018). Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. Nutrition & Metabolism. https://doi.org/10.1186/s12986-018-0295-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.